Recent Updates
Recently added Catalysts
IART Negative Sentiment Score: 25/100

Integra LifeSciences Holdings Corporation Investors: Please contact the Portnoy Law Firm to recover your losses; November 13, 2023 deadline

Key Takeaway: Integra LifeSciences Holdings Corporation is facing a lawsuit filed by investors due to alleged misleading statements and uncovered information regarding FDA violations. These violations relate to issues dating back to 2018, resulting in potential product recalls and a lack of progress in obtaining premarket approval for the SurgiMend product. The lawsuit claims that investors suffered financial losses as a result of these inadequate actions and the subsequent shutdown of the Boston Facility for necessary corrections.

Market Sentiment Analysis

CONCERNS & RISKS

  • Integra is facing a lawsuit due to alleged false statements and concealed information.
  • The company has been cited for FDA violations resulting in potential recalls of several products.
  • There has been no progress towards obtaining premarket approval for the SurgiMend product.
  • The ongoing violations at the Boston Facility led to its shutdown for corrective measures.

Full Press Release Details

Investors can contact the law firm at no cost to learn more about recovering their losses
LOS ANGELES, Oct. 11, 2023 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Integra LifeSciences Holdings Corporation (NASDAQ: IART) investors that a lawsuit filed on behalf of investors that purchased Integra securities between March 11, 2019 and May 22, 2023, both dates inclusive.
Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 844-767-8529 or email: lesley@portnoylaw.com, to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors’ options for pursuing claims to recover their losses.
According to the lawsuit, during the Class Period, the defendants were alleged to have made false statements and/or concealed information. This information pertained to Integra's failure to take adequate actions to address the violations that had been pointed out by the U.S. Food and Drug Administration ("FDA") in several instances: the Notice of Inspectional Observations on Form 483 issued on November 2, 2018, the FDA warning letter of March 6, 2019, and the Form 483 issued on November 12, 2021. Consequently, since March 2018, all products manufactured at Integra's Boston Facility, which includes SurgiMend, PriMatrix, Revize, and TissueMend, had the potential to contain levels of endotoxin exceeding the permitted limits, necessitating recalls.
Additionally, Integra was not making progress towards obtaining premarket approval ("PMA") for SurgiMend. One of the reasons for this lack of progress was the ongoing violation of FDA standards at the Boston Facility, a facility intended for producing the PMA product. Integra failed to rectify these violations even years after the initial notice, ultimately leading to the facility's shutdown for corrective measures. When the true facts regarding these matters became known, the lawsuit alleges that investors incurred financial losses.
Please visit our website to review more information and submit your transaction information.
The Portnoy Law Firm represents investors in pursuing claims against caused by corporate wrongdoing. The Firm’s founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes.
Lesley F. Portnoy, Esq.
Admitted CA and NY Bar
Attorney Advertising

Tags

Frequently Asked Questions

What investors should know about the Integra lawsuit?

A class action lawsuit is filed for investors who bought Integra securities from March 2019 to May 2023.

How can I contact the Portnoy Law Firm?

Investors can reach attorney Lesley F. Portnoy at 844-767-8529 or lesley@portnoylaw.com.

What issues did the Integra lawsuit highlight?

The lawsuit claims Integra made false statements and failed to address FDA violations.

What is the potential risk with Integra products?

Integra products may exceed endotoxin limits, posing safety risks and recalls.

What legal options do Integra investors have?

Investors can discuss recovery options and receive a free case evaluation from the firm.

Last updated: Oct 11, 2023